publication date: Jan. 4, 2019
NCI Trials NCI Trials for January
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I 10184
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
National Cancer Institute LAO
Saloura, Vassiliki
(301) 594-0911
Phase I 10219
Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Mayo Clinic Cancer Center LAO
Gonsalves, Wilson I.
(507) 266-0792
Phase II LUNGMAP
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
SWOG
Papadimitrakopoulou, Vassiliki A.
(713) 792-6363
Phase II S1801
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
SWOG
Patel, Sapna Pradyuman
(713) 792-2921
Phase II/III EA2174
A Phase II/III Study … Continue reading NCI Trials for January 2019
To access this members-only content, please log in.Institutional subscribers, please
log in with your IP.
If you're not a subscriber why not
join today? To gain access to the members only content
click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
